Meeting
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
A preclinical study of tumor-infiltrating lymphocytes in NSCLC.
Authors
Lorenzo Federico
The University of Texas MD Anderson Cancer Center, Houston, TX
Lorenzo Federico, Cara L. Haymaker, Marie-Andree Forget, Andrea Ravelli, Ankit Bhatta, Tatiana Karpinets, Ran Zhang, Annikka Weissferdt, Bingliang Fang, Jianjun Zhang, Tina Cascone, Ara A. Vaporciyan, Andrew Futreal, Ignacio Ivan Wistuba, Boris Sepesi, John Heymach, Don Lynn Gibbons, Chantale Bernatchez
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses,Hematologic Malignancies
Sub Track
Cell Therapies
Citation
J Clin Oncol 36, 2018 (suppl 5S; abstr 161)
DOI
10.1200/JCO.2018.36.5_suppl.161
Abstract #
161
Poster Bd #
K3
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Exploring the potential of combination immune checkpoint strategies in non-small cell lung cancer (NSCLC).
First Author: Aakash Desai
Poster
2024 ASCO Gastrointestinal Cancers Symposium
PD1 and CD39 expression on tumor infiltrating lymphocytes in patients with gastric cancer.
First Author: Takafumi Okayama
Poster
2021 ASCO Annual Meeting
Phase 2 study of PD-1 inhibitor JTX-4014 alone and in combination with vopratelimab, an ICOS agonist, in biomarker-selected subjects with metastatic NSCLC after one prior platinum-containing regimen (SELECT).
First Author: Oleh Kobziev
Poster
2020 ASCO Virtual Scientific Program
Targetable immune checkpoint molecules may be significantly differentially expressed in minority ethnicities.
First Author: Jacob J. Adashek